IA
CUE icon

IFP Advisors’s Cue Biopharma CUE Stock Holding History

IFP Advisors’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$150 Buy
103
+100
+3,333% +$2.26K ﹤0.01% 4905
2026
Q1 		$23 Hold
3
– – ﹤0.01% 4908
2025
Q4 		$31 Hold
3
– – ﹤0.01% 4759
2025
Q3 		$72 Hold
3
– – ﹤0.01% 4597
2025
Q2 		$68 Hold
3
– – ﹤0.01% 4777
2025
Q1 		$91 Hold
3
– – ﹤0.01% 3877
2024
Q4 		$109 Hold
3
– – ﹤0.01% 4002
2024
Q3 		$76 Hold
3
– – ﹤0.01% 3244
2024
Q2 		$124 Hold
3
– – ﹤0.01% 3162
2024
Q1 		$189 Hold
3
– – ﹤0.01% 3033
2023
Q4 		$264 Buy
+3
New +$214 ﹤0.01% 2922

Other funds holding CUE

RSWM
Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
GG
Gleason Group Prospect, Kentucky $1.15B AUM 21.11% 1-Year Est. Return
GSWM
Golden State Wealth Management Santa Ana, California $1.1B AUM 27.49% 1-Year Est. Return
PWA
Physician Wealth Advisors Midvale, Utah $837M AUM 26% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return

IFP Advisors's CUE Position: Q2 2026 in Review

IFP Advisors increased its Cue Biopharma (CUE) stake by 3,333% in Q2 2026, buying an estimated $2.26K and bringing the position to 103 shares worth $150. The position accounts for ﹤0.01% of the portfolio, ranked #4905.

IFP Advisors first reported a position in CUE in Q4 2023 and has held it in 11 quarters since. The position peaked at $264 in Q4 2023. 8 funds tracked by Wall St. Rank hold CUE as of Q2 2026.

  • IFP Advisors held 103 shares of Cue Biopharma worth $150 as of Q2 2026.
  • IFP Advisors bought 100 Cue Biopharma shares in Q2 2026, an estimated $2.26K.
  • Cue Biopharma made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #4905 holding.
  • IFP Advisors first reported a position in Cue Biopharma in Q4 2023 and has held it in 11 quarters since.
  • IFP Advisors's Cue Biopharma position peaked at $264 in Q4 2023.
  • 8 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.